著者

保坂 茂 山本 碧 斉藤 竜也 大島 新司 大嶋 繁 大島 公恵 久津間 信明 本間 精一 小林 大介

出版者

Japanese Society of Drug Informatics

雑誌

医薬品情報学 (ISSN:13451464)

巻号頁・発行日

vol.15, no.2, pp.64-70, 2013 (Released:2013-09-05)

参考文献数

14

---

Objective: In this study, we evaluated distinctive types of physical predisposition in patients with common side effects.Method: We selected 500 and 1,200 individuals with and without a previous diagnosis of side effects, respectively, through web-based research.  Then, we conducted a decision tree analysis for investigating the status of 100 types of physical predisposition in these individuals.Results and Conclusion: The individuals who had suffered from hepatic disorder and answered “relevant” for “predisposition to swelling” (likelihood ratio of a positive result [LR+] 2.17; p=0.004) and “very relevant” for “predisposition to skin dryness” (LR+ 3.52; p<0.001) enhanced the probability of extracting individuals who developed side effects.  The individuals who had suffered from skin disorder and answered “relevant” for “predisposition to eczema and inflammation” and “not relevant” for “predisposition to higher temperature” had an LR+ of 2.22 (p<0.001).  The individuals with “predisposition to worsening of physical condition on a rainy or high-humidity day” are more likely to develop side effects with the use of antibiotics and NSAIDs, compared to those without this predisposition (antibiotics: LR+ 2.33; NSAIDs: LR+ 2.51).  The results of this study indicate that we can identify patients with a high risk of side effects through an interview on predisposition.

著者

遠藤 敏成 久津間 信明 小林 大介 沼尻 幸彦 上田 秀雄 駒田 冨佐夫 齋藤 侑也 森本 雍憲

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.28, no.6, pp.615-622, 2002-12-10 (Released:2011-03-04)

参考文献数

6

---

When a pharmacist informs a patient of premonitory symptoms to prevent any adverse effects of each prescribed medicine, such instructions are often to complicated to be understood by the patients, mainly due to the fact that numerous medicines have a wide range of adverse effects, and furthermore, an such adverse effects have many premonitory symptoms. We attempted to make a computer aided adverse effect informing program to assist pharmacists. This program arranges the symptoms according to their order of importance, and gives the probable information of adverse effect, which is not mentioned in the package leaflet. The most frequent and common premonitory symptoms of adverse effect were suggested to be fever and fatigue as a result of running the program when many individual patient prescription data were inputted.The incorporation of this program into the computer system that manages the patient's medicine history will be useful for pharmacists to inform patients of understandable premonitory symptoms and to monitor any potential adverse effect.

著者

小林 大介 久津間 信明 中山 惠 鵜近 篤史 鈴木 暢之 佐次田 優子 遠藤 敏成 上田 秀雄 沼尻 幸彦 駒田 富佐夫 齋藤 侑也 森本 雍憲

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.28, no.6, pp.571-575, 2002-12-10 (Released:2011-03-04)

参考文献数

10

被引用文献数

2 1

---

When a novel additional adverse effect is reported for a marketed medicine, the medical information leaflet has to be revised to inform physicians and pharmacists of this. Pharmacists are responsible for informing patients of early warning symptoms to avoid the subsequent appearance of severe adverse effects. However, at present, patients may suffer from severe adverse events because such symptoms may remain unrecognized until the medicine is on the market. As a result, investigations to predict and prevent novel additional adverse effects of medicines are required. In this study, we investigated a novel additional adverse effect classified as a pharmacological effect based on the drug safety update (DSU). As a result, skin disorders including toxic epidermal necrolysis and Stevens Johnson syndrome, and pseudomembranous colitis have become evident as additional adverse effects of antibiotics, with a high incidence. In addition, neuroleptic malignant syndrome and aplastic anemia have also been reported as adverse effects of central nervous system agents.Therefore, it is important to provide patients with information about the early warning symptoms related to such adverse effects, even though such adverse effects are not contained in the patient information leaflet.